CRISPR Enzymes and Systems

ChangeBridge: Patent Apps - Biotech (C12N)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

The USPTO published patent application US20260092266A1 by Feng Zhang et al. for engineered CRISPR-Cas systems comprising multimeric complexes with β-CASP polypeptides and small Type II-B, II-C, and II-D Cas proteins for modifying target polynucleotides. The application (No. 19388533) was filed November 13, 2025, and published April 2, 2026.

View original document View source feed page

What changed

The USPTO published a patent application for engineered CRISPR-Cas gene editing systems developed by Feng Zhang, Han Altae-Tran, and Soumya Kannan. The application covers multimeric CRISPR-Cas complexes containing β-CASP polypeptides, multiple Cas polypeptides, and guide molecules, as well as small Cas proteins from Type II-B, II-C, and II-D categories, including packaging and delivery systems and methods for modifying target polynucleotides.

This is a standard patent publication providing public notice of a biotechnology invention. No compliance actions are required from other entities. Companies developing gene therapies or CRISPR-based applications should review the published claims to assess potential IP overlap with their own research programs.

Source document (simplified)

← USPTO Patent Applications

CRISPR ENZYMES AND SYSTEMS

Application US20260092266A1 Kind: A1 Apr 02, 2026

Inventors

Feng Zhang, Han Altae-Tran, Soumya Kannan

Abstract

Described herein are engineered, non-naturally occurring systems and compositions comprising multimeric CRISPR-Cas complexes comprising a β-CASP polypeptide, a plurality of Cas polypeptides, and a guide molecule, packaging and delivery systems thereof, and methods of use thereof, for modifying target polynucleotides. In addition, described herein are engineered, non-naturally occurring systems and compositions comprising a class of small Cas proteins (Type II-B, II-C, and II-D Cas proteins) and methods of modifying target sequences using the Type II-B, II-C, II-D Cas proteins and systems thereof.